Revolutionizing the Treatment of Cancer
|
|
- Ronald Cobb
- 5 years ago
- Views:
Transcription
1 Revolutionizing the Treatment of Cancer September 2013
2 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may differ materially from anticipated results, and expectations expressed in these forward looking statements, as a result of certain risks and uncertainties, including Rexahn's lack of profitability, the need for additional capital to operate its business to develop its product candidates; the risk that Rexahn's development efforts relating to its product candidates may not be successful; the possibility of being unable to obtain regulatory approval of Rexahn's product candidates; the risk that the results of clinical trials may not be completed on time or support Rexahn's claims; demand for and market acceptance of Rexahn's drug candidates; Rexahn's reliance on third party researchers and manufacturers to develop its product candidates; Rexahn's ability to develop and obtain protection of its intellectual property; and other risk factors set forth from time to time in our filings with the Securities and Exchange Commission. Rexahn assumes no obligation to update these forward looking statements. 2
3 Rexahn: Revolutionizing the Treatment of Cancer Identify novel drug targets which are specific to cancer cells: Increased efficacy, reduced toxicity Efficacy against multiple drug resistant cancer cells Synergism with existing cytotoxic compounds Nano Polymer Drug Conjugate System (NPDCS) combines existing anticancer agents with a polymer/signaling moiety which directs the drug directly to the tumor: Lower risk strategy that utilizes clinically proven anticancer drugs Maximizes drug levels in the cancer tumor and minimizes circulating drug levels Maximizing efficacy and minimizing toxicity 3
4 Rexahn Investment Highlights Rapidly advancing pipeline: Initiating three clinical trials in 2013 with data in 2014 Pipeline Archexin: Akt1 inhibitor in Phase II clinical development for pancreatic cancer, and an additional indication RX 3117: DNA synthesis inhibitor completed successful exploratory Phase I trial in solid tumors IND cleared FDA and Phase I clinical development will be initiated in 4Q13 Supinoxin (RX 5902): p68 RNA Helicase inhibitor. Phase I clinical trial in cancer patients with solid tumors ongoing Nano Polymer Drug Conjugate System (NPDCS) RX 21101: polymer conjugated form of docetaxel containing a signaling moiety which directs the drug into the tumor maximizing efficacy and minimizing toxicity Strong Intellectual Property position 4
5 Deep Oncology Pipeline Drug Candidate Mechanism of Action Preclinical Phase I Phase II Phase III Archexin RX 3117 Akt1 Inhibitor DNA Synthesis Inhibitor Supinoxin TM (RX 5902) p68 RNA Helicase Inhibitor Nano Polymer Drug Conjugate System (NPDCS) RX Docetaxel Conjugate 5
6 Financial Highlights As of September 1, 2013, cash and cash equivalents on hand totaled approximately $15.7 million For the six month period ended June 30, 2013, total operating expenses were $3.8 million Burn rate of $0.9M/month expected for next 12 months million shares of common stock outstanding 6
7 New and Experienced Management Team Peter D. Suzdak Ph.D., (CEO) CEO as of February 2013 Over 28 years of experience in pharmaceutical industry Formerly at Corridor Pharma, Cardioxyl Pharma, Guilford Pharmaceuticals, Novo Nordisk A/S, NIH, Pfizer Rick Soni, M.B.A., (President & COO) Over 25 years of experience in pharmaceutical industry Formerly at Otsuka America Pharmaceuticals, Novartis, and Schering Plough Ted Jeong, D.Mgt., (Sr. VP & CFO) Over 16 years of experience in capital raising and investment Formerly at Hyundai Venture Investment Corporation 7
8 RX 3117
9 RX 3117: Best in Class Antimetabolite Nucleoside Mechanism Current and Future Indications Advantages Patent Clinical Development Inhibition of DNA synthesis Induction of apoptotic cell death Activated by UCK, which is different from gemcitabine Solid tumors: pancreas, NSCLC, colon, renal and other solid tumors Better efficacy and safety than gemcitabine in animal models Activity against gemcitabine resistant cancer cells Superior pharmacokinetic profile compared to gemcitabine: active following oral administration and longer half life Potential market leader in gemcitabine market Patent expires in 2024 Completed exploratory clinical trial in cancer patients for oral bioavailability, safety and pharmacokinetics IND filed (July 2013) and Phase I trial in cancer patients anticipated to start in 2H13 9
10 RX 3117: Status Investigational New Drug (IND) application for RX 3117 was submitted in July 2013 and has now cleared the 30 day review period by the US Food and Drug Administration (FDA) Rexahn expects to initiate a Phase I clinical trial in cancer patients with solid tumors during the fourth quarter of 2013 Rexahn will be exploring potential partnering opportunities with oncology focused pharmaceutical companies Original deal with Teva was an early preclinical deal Any future deal will be a clinical stage deal with superior financial terms 10
11 RX 3117: Termination of Collaboration with Teva Collaboration with Teva terminated August 2013 Teva has invested $9.1M in the development of RX 3117 According to Teva RX 3117 appears to have potential in various indications, but does not align with Teva s new Oncology strategy Therapeutic core areas of focus to be Neurology and Respiratory therapeutic areas Teva has terminated a total of 15 programs in the past 2 years Teva to cut $2B in expenses in next 5 years* Teva has terminated four Oncology programs in the past 12 months (CT 011 (Curetech), Lyndor Bioscience, Obatoclax (Cephalon))* * Teva Investor Day Presentation, December 2012, subsequent Teva press releases and FierceBiotech 2012,
12 RX 3117: Exploratory Phase I clinical Trial (Completed) Exploratory Phase I clinical trial of RX 3117 in cancer patients conducted in Europe in 2012 Oral administration of RX 3117 demonstrated an oral bioavailability of 56% and a plasma half life (T 1/2 ) of 14 hours Superior profile compared to gemcitabine RX 3117 was safe and well tolerated in all subjects throughout the dose range tested 12
13 RX 3117: Preclinical Data Broad spectrum anti tumor activity against 50 different human cancer cell lines Efficacy in 12 mouse xenograft models superior to that of gemcitabine In human cancer cell lines made resistant to the anti tumor effects of gemcitabine, RX 3117 still retains its full anti tumor activity Tumor volume (mm 3 ) Days Colo-205 xenograft mice model 13
14 RX 3117 Phase I Clinical Trial Design Dose escalation study to determine safety and efficacy in patients with solid tumors Decision to escalate dose made by external safety review committee approximately 14 days after first cycle is complete Patients have the possibility to receive up to 8 cycles of treatment Patients are scanned (CT or MRI) for assessment of solid tumors Scan is repeated at the end of every 2 cycles of treatment Initiate in 4Q13 Initial clinical data available in 2H14 14
15 Archexin
16 Archexin: Best in Class Akt1 Inhibitor Mechanism Inhibitor of the protein kinase Akt1 Involvement in tumor cell growth, survival and angiogenesis Inhibition of Akt1 mediated drug resistance Clinical Development Phase I trial in cancer patients completed Pancreatic cancer Phase IIa completed Phase IIa trial to begin in 2H13 Advantages Patent Targeting a major signal system Excellent safety profile in humans Orphan designations for 5 cancers (pancreatic cancer, ovarian cancer, stomach cancer, RCC, glioblastoma) Patent expires in
17 Archexin s Attractive Commercial Opportunity ARCHEXIN is: Well POSITIONED to address unmet medical needs in Pancreatic, Ovarian and Stomach cancer, Renal cell carcinoma, Glioblastoma (all orphan drug designation granted by the FDA), Prostate and Hematological malignancies EFFECTIVE in combination with gemcitabine reducing risk and safety concerns increased efficacy A NOVEL modality, EASY to manufacture and has a follow on targeted nano formulation that will afford INCREASED life cycle management Percentage of patients Renal Cell Carcinoma Current Unmet Medical Need Treated Patients Ovarian Prostate Pancreatic Multiple sources: Decision Resources, Feb 2010 targeted oncology market report, Cancer.gov, NCI 17
18 Target: Akt1 Significant increase in the activated form of Akt1 (Phosphorylated Akt1) in cancer cells Results in increased tumor cell growth/size, proliferation, survival, neovascularization and resistace to cytotoxic agents Native Akt1 Activated Akt1 mrna expression of Akt1 Archexin selectively blocks the native and activated forms of Akt1 18
19 Archexin: Phase I Clinical trial (completed) Phase I objective To determine maximum tolerated dose, safety and pharmacokinetic profiles Phase I results: MTD was 250 mg/m 2 /d in Patients with an advanced cancer after up to two cycles of treatment The dose limiting toxicity was Grade 3 fatigue; no significant hematological abnormalities Phospho Akt1 being developed as a clinical biomarker J Clin Onc, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007:
20 Archexin: Phase IIa Study in Metastatic Pancreatic Cancer (completed) Archexin in combination with gemcitabine was safe, well tolerated and demonstrated preliminary signs of efficacy in patients with advanced pancreatic cancer Open label 2 stage study to assess the safety and efficacy of Archexin in combination with gemcitabine 31 subjects enrolled (10 for safety, 21 for efficacy) with ages ranging years with metastatic pancreatic cancer Archexin in combination with gemcitabine provided a median survival of 9.1 months compared to the historical survival data of 5.65 months (Burris et al., 1997, J. Clin Oncol 15:2403) for standard single agent gemcitabine therapy Most frequently reported adverse events include constipation, nausea, abdominal pain, and pyrexia, regardless of relatedness 20
21 Archexin: Potent anti proliferative effects against cancer cell lines expressing activated Akt1 Archexin potently inhibits the growth of cancer cell lines containing activated Akt1 Board spectrum of potential clinical utility 21
22 Archexin: Clinical Development Plan Expand Phase II program to include additional cancer types with increased activated Akt1 A scientific, clinical and business analysis of potential indications for a Phase IIa clinical trial with Archexin has been completed Rexahn is now working with key clinical opinion leaders to finalize the design of a Phase IIa clinical trial in a selected tumor type Rexahn anticipates updating investors on the tumor type selection and Phase IIa trial timeline early in the fourth quarter of
23 Supinoxin TM (RX 5902)
24 Supinoxin: Best in Class p68 Helicase Inhibitor Mechanism Inhibition of p68 RNA helicase Blocks upregulation of cancer related genes Current and Future Indications Solid tumors: pancreas, NSCLC, colon, renal and other solid tumors Advantages Anti proliferative effects Synergistic with cytotoxic agents Efficacy against drug resistant cancer cells Orally bioavailable Patent Patent expires in 2025 Clinical Development IND filed Phase I clinical trial in cancer patients ongoing 24
25 Supinoxin s Attractive Commercial Opportunity Supinoxin is: EFFECTIVE against most difficult cancers Melanoma, Renal Cell Carcinoma, Ovarian and Pancreatic cancer (fastest growing drugtreatable pool populations*) EFFECTIVE against multi drug resistance, based on resistance reversing effects in drug resistant cancer cells EFFECTIVE as a combination therapy growth inhibition of cancer cells in combination with leading anticancer drugs CONVENIENT Oral availability will increase patient compliance Percentage of patients Current Unmet Medical Need Treated Patients Melanoma Renal Cell Carcinoma Ovarian Pancreatic Multiple sources: Decision Resources, Feb 2010 targeted oncology market report, Cancer.gov, NCI 25
26 Supinoxin: Mechanism of action Summary Phosphorylated p68 is highly expressed in cancer cells (not in normal cells) Results in upregulation of cancer related genes P p68 Resulting in cancer cell proliferation/tumor growth Supinoxin Selectively blocks Phosphorylated p68 Decreased proliferation/growth of cancer cells Synergism with cytotoxic agents Activity against drug resistant cancer cells Upregulation of Cyclin D1, C jun and C myc Cancer cell Proliferation/Tumor growth 26
27 Supinoxin: Phase I Clinical Trial Ongoing Conducted at three clinical oncology centers in the United States Dose escalation design Decision to escalate the dose will be made after one cycle of treatment, based on safety and tolerability Each patient will then have the ability to continue on drug for a total of six cycles of treatment. Patients will be assessed by CT or MRI prior to the start of therapy and after every two cycles of therapy for tumor progression Rexahn anticipates updating investors on this Phase I trial in early
28 Supinoxin: Increased Survival in Human Renal Cell Carcinoma and Pancreatic Cancer Xenograft Models 28
29 Nano Polymer Drug Conjugate System (NPDCS)
30 Nano Polymer Drug Conjugate System (NPDCS) Combines existing chemotherapeutic agents with a proprietary polymer carrier that contains a signaling moiety which directs the drug directly into the tumor Minimizes the levels of freely circulating drug thereby reducing potential adverse events Maximizes accumulation of drug in the tumor thereby increasing antitumor activity NPDCS is a broad platform that has the potential to generate multiple drug candidates going forward First drug candidate: RX 21101, a polymer conjugated form of docetaxel Preclinical studies demonstrated increased efficacy and reduced toxicity, as compared to intravenously administered free docetaxel. 30
31 Corporate Overview Milestones Highlights
32 Major Milestones in 2013/2014 Filed RX 3117 IND (July 2013) In licensed Nano Polymer Drug Conjugate System (NPDCS) (July 2013) First cancer patient dosed with Supinoxin TM (RX 5902) (August 2013) Initiate Phase II clinical study with Archexin (4Q13) Initiate Phase I clinical study with RX 3117 in cancer patients with solid tumors (4Q13) Initial data from RX 5902 Phase I clinical study (3Q14) Initial data from Archexin Phase II studies (4Q14) Initial data from RX 3117 Phase I clinical trial (4Q14) 32
33 Financial Highlights Rexahn Financial Highlights Ticker RNN Exchange NYSE MKT Market Price (9/6/13) $0.48 Market Capitalization (9/6/13) $64 MM Shares Outstanding (9/6/13) MM Insider Ownership 10% Cash Balance (9/1/13) $15.7 MM Monthly Est. Cash Burn $0.9 MM 33
34 Rexahn Investment Highlights Rapidly advancing pipeline: Initiating three clinical trials in 2013 with data in 2014 Pipeline Archexin: Akt1 inhibitor in Phase II clinical development for pancreatic cancer, and a additional indication RX 3117: DNA synthesis inhibitor completed successful exploratory Phase I trial in solid tumors IND cleared FDA and Phase I clinical development will be initiated in 4Q13 Supinoxin (RX 5902): p68 RNA Helicase inhibitor. Phase I clinical trial in cancer patients solid tumors ongoing Nano Polymer Drug Conjugate System (NPDCS) RX 21101: polymer conjugated form of docetaxel containing a signaling moiety which directs the drug into the tumor maximizing efficacy and minimizing toxicity Strong Intellectual Property position 34
35 Revolutionizing the Treatment of Cancer REXAHN PHARMACEUTICALS, INC Shady Grove Road, Suite 455 Rockville, MD Tel Fax
Revolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More informationRexahn Pharmaceuticals Overview
Rexahn Pharmaceuticals Overview May 2018 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn s actual results may differ
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationCorporate Overview. July 2016 NASDAQ: CYTR
Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE
More informationCorporate Overview. May 2017 NASDAQ: CYTR
Corporate Overview May 2017 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationInfinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results
Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results Heat Shock Protein 90 Program Continues to Advance Toward Potential Registration Trial CAMBRIDGE, Mass.,
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationNewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationDicerna Pharmaceuticals Overview. Delivering RNAi-Based Breakthrough Therapies
Pharmaceuticals Overview Delivering RNAi-Based Breakthrough Therapies Forward-Looking Statements This information may contain projections and other forward looking statements regarding future events, including
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationCOMPANY OVERVIEW. June CytomX Therapeutics, Inc.
COMPANY OVERVIEW June 2016 2016 CytomX Therapeutics, Inc. Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation may contain projections and other forward-looking
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationNASDAQ: CYTR FIGHTING CANCER WITH CUTTING EDGE SCIENCE. Corporate Overview. July 2018
NASDAQ: CYTR Corporate Overview July 2018 CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationCalliditas Therapeutics Q2 Report Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Calliditas Therapeutics Q2 Report 2018 Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation may contain certain
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationEmisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results
August 11, 2008 Emisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results Conference Call/Webcast to be Held Monday, August 11 at 10:00 AM EDT CEDAR KNOLLS, N.J., Aug 11, 2008 /PRNewswire-FirstCall
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationSafe Harbor Statement
September 2007 Safe Harbor Statement During the course of this presentation we will make forward-looking statements that involve risks and uncertainties associated with a developing pharmaceutical company.
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More informationMyeloid Differentiation Observed, Including Induction of CD38 in 85% of Evaluable Patients
December 10, 2017 Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients Clinical
More informationNEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan
NEWS RELEASE Media Contact: Megan Pace 650-467-7334 Investor Contact: Kathee Littrell 650-225-1034 Patient Inquiries: Ajanta Horan 650-467-1741 GENENTECH RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationSpectrum Pharmaceuticals
Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationMOLOGEN AG. Pioneering Immune Therapy. Q1 Results 2014 Conference Call. Dr. Matthias Schroff, CEO
Pioneering Immune Therapy Q1 Results 2014 Conference Call Dr. Matthias Schroff, CEO Berlin, 14 May 2014 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to
More informationNEWS RELEASE Media Contact: Krysta Pellegrino (650) Investor Contact: Sue Morris (650) Advocacy Contact: Kristin Reed (650)
NEWS RELEASE Media Contact: Krysta Pellegrino (650) 225-8226 Investor Contact: Sue Morris (650) 225-6523 Advocacy Contact: Kristin Reed (650) 467-9831 FDA APPROVES AVASTIN IN COMBINATION WITH CHEMOTHERAPY
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationUnder the terms of the agreement, AVEO will receive an initial cash payment of $125 million, composed of a $75 million license fee and $50 million in
Astellas Pharma Inc. AVEO Pharmaceuticals Corporate Communications Investor Contact: Astellas Pharma Inc. Monique Allaire AVEO Pharmaceuticals +81(3)-3244-3201 (617) 299-5810 Media Contact: Dan Budwick
More informationBayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye in Wet Age-related Macular Degeneration
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye in Wet Age-related Macular Degeneration International
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationCorporate Presentation Fourth Quarter 2017
Corporate Presentation Fourth Quarter 2017 November 2017 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationSumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)
December 21, 2016 Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company) Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka,
More information9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO
9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO BERLIN, 13 NOVEMBER, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationStifel Healthcare Conference John Scarlett, M.D. Chief Executive Officer November 19, 2014
Stifel Healthcare Conference 2014 John Scarlett, M.D. Chief Executive Officer November 19, 2014 1 forward-looking statements Except for statements of historical fact, the statements during this presentation
More informationCorporate Overview NASDAQ: CLRB
Corporate Overview NASDAQ: CLRB Safe Harbor Statement 2 This presentation contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this
More informationArming the patient s immune system to fight cancer
Arming the patient s immune system to fight cancer Redeye - Fight Cancer Seminar 10 th March 2017 Øystein Soug, CEO Important notice and disclaimer This report contains certain forward-looking statements
More informationCorporate Presentation. October 2017
AEPP Breakthrough technology for women s cancers Corporate Presentation October 2017 Oncolix 2017 1 Safe Harbor Certain of the statements and the projections set forth in this presentation constitute forward-looking
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationArgos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results
March 27, 2014 Argos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results - AGS-003 Phase 3 ADAPT Trial on Track to Complete Enrollment This Year - - AGS-004-Induced Immune Responses
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationMANIFEST Phase 2 Enhancement / Expansion
MANIFEST Phase 2 Enhancement / Expansion Investor Conference Call Stellar Science, Breakthrough Medicine October 11, 2018 Forward-Looking Statements This presentation contains forward-looking statements
More informationInvestor Presentation
Investor Presentation June 2017 Joe Turgeon President and Chief Operating Officer Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance
More informationMerrimack Pharmaceuticals: A Refocused R&D Company January 2017
Merrimack Pharmaceuticals: A Refocused R&D Company January 2017 Forward Looking Statements This presentation contains forward-looking statements of the Company that involve substantial risks and uncertainties.
More informationAradigm Corporation. A respiratory specialty pharmaceutical company fulfilling unmet needs in pulmonary medicine (ARDM) February 2008
Aradigm Corporation A respiratory specialty pharmaceutical company fulfilling unmet needs in pulmonary medicine (ARDM) February 2008 Safe Harbor Statement This presentation contains forward-looking statements
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationPresentation to AGM 9 November Deborah Rathjen CEO & Managing Director
Presentation to AGM 9 November 2011 Deborah Rathjen CEO & Managing Director Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward looking" statements within the
More informationOncoSec Provides 2018 Business Outlook
January 3, 2018 OncoSec Provides 2018 Business Outlook Complete stage 1 enrollment of PISCES/KEYNOTE-695 clinical trial of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) Present preliminary
More informationLEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017
LEERINK GLOBAL HEALTHCARE CONFERENCE Marino Garcia EVP, Chief Strategy Officer February 15, 2017 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting
More informationTranslating cancer biology into medicines BIO CEO Investor Conference NASDAQ CYCC - February 12, 2018
CYC 682 Translating cancer biology into medicines BIO CEO Investor Conference NASDAQ CYCC - February 12, 2018 Disclaimer This presentation contains forward-looking statements within the meaning of the
More informationDARA Reports Year-End 2012 Financial Results
April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationJefferies Healthcare Conference. June 25, 2008
Jefferies Healthcare Conference June 25, 2008 Safe Harbor Statement Except for the historical information set forth herein, the matters set forth in this presentation,including without limitation statements
More informationActinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting
December 4, 2018 Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting - Key highlights include near universal engraftment
More informationKaryopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress
August 10, 2015 Karyopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress - Positive Selinexor Clinical Data Presented across Several Difficult to Treat Cancers - - Provides
More informationJP Morgan Healthcare Conference. January 8, 2007
JP Morgan Healthcare Conference January 8, 2007 Safe Harbor Statement Except for the historical information set forth herein, the matters set forth in this presentation,including without limitation statements
More informationGW Pharmaceuticals plc. Investor Presentation August 2014
GW Pharmaceuticals plc Investor Presentation August 2014 Forward Looking Statements and Disclaimer This presentation contains forward-looking statements. Some of the matters discussed concerning our operations
More informationMOLOGEN AG. Our research for you. Annual Results Analysts Call March 21, 2013
Our research for you. Annual Results 2012 Analysts Call March 21, 2013 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments,
More informationPierre Legault CEO June 2, 2014
April 2012 Pierre Legault CEO June 2, 2014 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationTransCode Therapeutics, Inc All Rights Reserved
1 Disclaimers THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE SECURITIES ACT ) OR THE SECURITIES LAWS OF ANY STATE AND ARE BEING OFFERED AND SOLD
More informationTargeted Therapeutics for Inflammatory Disease
Targeted Therapeutics for Inflammatory Disease Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial
More informationBioCryst Pharmaceuticals
BioCryst Pharmaceuticals Jefferies 2010 Global Life Sciences Conference New York Stuart Grant Senior Vice President & Chief Financial Officer Rob Bennett Executive Director, Investor Relations & Business
More informationCapricor Therapeutics
Therapeutics Conference Call to Discuss the HOPE-2 Clinical Trial NASDAQ: CAPR November 29, 2017 Forward-Looking Statements Statements in this presentation regarding the efficacy, safety, and intended
More informationmicrorna Therapeutics Harnessing the power of micrornas to target multiple pathways of disease
microrna Therapeutics Harnessing the power of micrornas to target multiple pathways of disease January 2018 Safe Harbor Statement Statements contained in this presentation regarding matters that are not
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More information[ NASDAQ: MEIP ] August 2014
[ NASDAQ: MEIP ] August 2014 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may differ materially from those
More informationMOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014
Pioneering Immune Therapy Annual Results 2013 Analysts Call March 25, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
More information36th Annual J.P. Morgan Healthcare Conference. Kevin Conroy, Chairman and CEO January 9, 2018
36th Annual J.P. Morgan Healthcare Conference Kevin Conroy, Chairman and CEO January 9, 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationMemory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance-
Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia -Broadens Roche Nicotinic Alpha-7 Alliance- -Secures Additional $5M Debt Financing to Support Phase 2a Trial-
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationVolitionRx Announces First Quarter 2016 Financial Results and Business Update
May 13, 2016 VolitionRx Announces First Quarter 2016 Financial Results and Business Update NAMUR, Belgium, May 13, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More informationSavolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer
Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer Initiation of expanded Phase II trials in NSCLC triggers US$10 million milestone from AstraZeneca to Chi-Med New study
More informationFor personal use only
Targeted DEP shows sustained superior performance in ovarian cancer model Melbourne, Australia; 2 February 2016: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced the final results of the preclinical
More informationINTERIM MANAGEMENT STATEMENT Q3 2017
INTERIM MANAGEMENT STATEMENT Q3 2017 Significant progress across all clinical programs New pre-clinical immunooncology data to be presented during R&D Day in New York Research & Development highlights:
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2015 Global Healthcare Conference Peter P. Pfreundschuh, VP Finance and CFO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2015 Global Healthcare Conference Peter P. Pfreundschuh, VP Finance and CFO Forward-Looking Statements This
More informationSAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines
SAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines Presented by Dan Browne, Co-Founder, President & CEO, and
More informationBayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies
More informationBobby W. Sandage, Jr., PhD President & Chief Executive Officer. Lazard Capital Markets 8 th Annual Healthcare Conference
Bobby W. Sandage, Jr., PhD President & Chief Executive Officer Lazard Capital Markets 8 th Annual Healthcare Conference Statements in this presentation that are not descriptions of historical facts are
More informationBuilding a Stroke Portfolio. June 28, 2018
Building a Stroke Portfolio June 28, 2018 1 Forward-Looking Statements This presentation contains forward-looking statements, including statements relating to: the potential benefits, safety and efficacy
More informationPhoenix Molecular Designs
Phoenix Molecular Designs DESIGNING PRECISE THERAPEUTICS TO REVOLUTIONIZE TREATMENT Our Team Dr. Sandra Dunn, Ph.D. Dr. Anna Stratford, Ph.D. Dr. Aarthi Jayanthan, Ph.D. Dr. Zaihui Zhang CEO, CSO UBC Professor
More informationJefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer
Jefferies 2016 Healthcare Conference Reid Huber, PhD Chief Scientific Officer June 8, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this
More information